Edition:
United States

Hologic Inc (HOLX.OQ)

HOLX.OQ on NASDAQ Stock Exchange Global Select Market

40.12USD
2:44pm EST
Change (% chg)

$0.40 (+1.01%)
Prev Close
$39.72
Open
$39.62
Day's High
$40.19
Day's Low
$39.50
Volume
283,665
Avg. Vol
882,902
52-wk High
$46.80
52-wk Low
$35.78

Chart for

About

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays,... (more)

Overall

Beta: 0.92
Market Cap(Mil.): $11,140.41
Shares Outstanding(Mil.): 280.47
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 29.40 15.80
EPS (TTM): -- -- --
ROI: -- 10.14 12.07
ROE: -- 15.42 16.02

BRIEF-Hologic announces upcoming put option

* Hologic announces upcoming put option and notice of redemption of 2.00% convertible senior notes due 2043 Source text for Eikon: Further company coverage:

Nov 14 2017

BRIEF-Hologic announces Q4 GAAP earnings per share $0.29

* Hologic announces financial results for fourth quarter of fiscal 2017

Nov 08 2017

BRIEF-Hologic - ‍received 510(k) clearance from FDA for Panther Fusion Paraflu assay​

* Hologic Inc - ‍received 510(k) clearance from FDA for Panther Fusion Paraflu assay​ Source text for Eikon: Further company coverage:

Oct 26 2017

BRIEF-Hologic prices offering of $350 mln 4.375 pct senior notes due 2025

* Hologic announces pricing of offering of $350 million aggregate principal amount of 4.375% senior notes due 2025

Oct 04 2017

BRIEF-Hologic announces offering of $350 mln of senior notes due 2025

* Hologic announces offering of $350 million of senior notes due 2025

Oct 04 2017

BRIEF-Hologic enters into amended and restated five-year secured credit agreement

* Hologic enters into amended and restated five-year secured credit agreement

Oct 04 2017

BRIEF-Hologic receives FDA 510(k) clearance to market SculpSure

* Hologic receives FDA 510(k) clearance to market SculpSure for non-invasive body contouring (lipolysis) of the submental area (under the chin)

Sep 27 2017

BRIEF-Hologic updates on commercial availability of Brevera Breast Biopsy System

* Hologic inc - ‍U.S. commercial availability of Brevera Breast Biopsy System with Corlumina imaging technology​ Source text for Eikon: Further company coverage:

Aug 31 2017

BRIEF-Hologic updates on FY17 profit outlook

* Hologic says ‍updated Q3 financial results press release to correct tax impact of certain exclusions in FY net income per share guidance​ - SEC filing

Aug 03 2017

BRIEF-Hologic Q3 GAAP earnings per share $0.21

* Hologic announces financial results for third quarter of fiscal 2017

Aug 02 2017

Competitors

Earnings vs. Estimates